Correction: Integrating multi-omics for uncovering the architecture of cross-talking pathways in breast cancer (PLoS ONE (2014) 9:8 (e104282) DOI:10.1371/journal.pone.0104282);Integrating multi-omics for uncovering the architecture of cross-talking pathways in breast cancer

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Wang, Li ^a   Xiao, Yun ^a   Ping, Yanyan ^a   Li, Jing ^b   Zhao, Hongying ^a   Li, Feng ^a   Hu, Jing ^a   Zhang, Hongyi ^a   Deng, Yulan ^a   Tian, Jiawei ^a   Li, Xia ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b HEILONGJIANG UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN; TUMOR PROTEIN;

ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; DNA METHYLATION; GENE DOSAGE; GENE EXPRESSION PROFILING; HUMAN; MAJOR CLINICAL STUDY; MOLECULAR INTERACTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TUMOR GENE; BOOK; BREAST TUMOR; COPY NUMBER VARIATION; FEMALE; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETICS; HUMAN GENOME; MAMMARY GLAND; METABOLISM; MUTATION; PATHOLOGY; PROTEOMICS;

ATLASES AS TOPIC; BREAST NEOPLASMS; DNA COPY NUMBER VARIATIONS; DNA METHYLATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; GENOME, HUMAN; HUMANS; MAMMARY GLANDS, HUMAN; MITOGEN-ACTIVATED PROTEIN KINASES; MUTATION; NEOPLASM PROTEINS; PROTEOMICS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 84940292859     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0221483     Document Type: Erratum

References (53)

1. Fousteri M, Mullenders LH (2008) Transcription-coupled nucleotide excision repair in mammalian cells: molecular mechanisms and biological effects. Cell Res 18: 73-84.
2. Ballif BA, Blenis J (2001) Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals. Cell Growth Differ 12: 397-408. (Pubitemid 32762689)
3. Logue JS, Morrison DK (2012) Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy. Genes Dev 26: 641-650.
4. Bernards R (2012) A missing link in genotype-directed cancer therapy. Cell 151: 465-468.
5. Li Y, Agarwal P, Rajagopalan D (2008) A global pathway crosstalk network. Bioinformatics 24: 1442-1447. (Pubitemid 351850998)
6. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, et al. (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18: 11-22.
7. Shenker N, Flanagan JM (2012) Intragenic DNA methylation: implications of this epigenetic mechanism for cancer research. Br J Cancer 106: 248-253.
8. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, et al. (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486: 346-352.
9. Negrini S, Gorgoulis VG, Halazonetis TD (2010) Genomic instability-an evolving hallmark of cancer. Nat Rev Mol Cell Biol 11: 220-228.
10. Zografos G, Liakakos T, Roukos DH (2013) Deep sequencing and integrative genome analysis: approaching a new class of biomarkers and therapeutic targets for breast cancer. Pharmacogenomics 14: 5-8.
11. Holm K, Hegardt C, Staaf J, Vallon-Christersson J, Jonsson G, et al. (2010) Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns. Breast Cancer Res 12: R36.
12. Kobayashi Y, Absher DM, Gulzar ZG, Young SR, McKenney JK, et al. (2011) DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. Genome Res 21: 1017-1027.
13. De Carvalho DD, Sharma S, You JS, Su SF, Taberlay PC, et al. (2012) DNA methylation screening identifies driver epigenetic events of cancer cell survival. Cancer Cell 21: 655-667.
14. Muggerud AA, Ronneberg JA, Warnberg F, Botling J, Busato F, et al. (2010) Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res 12: R3.
15. Xiao Y, Guan J, Ping Y, Xu C, Huang T, et al. (2012) Prioritizing cancer-related key miRNA-target interactions by integrative genomics. Nucleic Acids Res 40: 7653-7665.
16. Chang HH, McGeachie M (2011) Phenotype prediction by integrative network analysis of SNP and gene expression microarrays. Conf Proc IEEE Eng Med Biol Soc 2011: 6849-6852.
17. (2012) Comprehensive genomic characterization of squamous cell lung cancers. Nature 489: 519-525.
18. Kim D, Shin H, Song YS, Kim JH (2012) Synergistic effect of different levels of genomic data for cancer clinical outcome prediction. J Biomed Inform 45:1191-1198.
19. Xiao Y, Xu C, Ping Y, Guan J, Fan H, et al. (2011) Differential expression pattern-based prioritization of candidate genes through integrating diseasespecific expression data. Genomics 98: 64-71.
20. Mosca E, Alfieri R, Merelli I, Viti F, Calabria A, et al. (2010) A multilevel data integration resource for breast cancer study. BMC Syst Biol 4: 76.
21. Chari R, Coe BP, Vucic EA, Lockwood WW, Lam WL (2010) An integrative multi-dimensional genetic and epigenetic strategy to identify aberrant genes and pathways in cancer. BMC Syst Biol 4: 67.
22. Hebestreit K, Grottrup S, Emden D, Veerkamp J, Ruckert C, et al. (2012) Leukemia gene atlas - a public platform for integrative exploration of genomewide molecular data. PLoS One 7: e39148.
23. Tang W, Duan J, Zhang JG, Wang YP (2013) Subtyping glioblastoma by combining miRNA and mRNA expression data using compressed sensing-based approach. EURASIP J Bioinform Syst Biol 2013: 2.
24. Setty M, Helmy K, Khan AA, Silber J, Arvey A, et al. (2012) Inferring transcriptional and microRNA-mediated regulatory programs in glioblastoma. Mol Syst Biol 8: 605.
25. Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, et al. (2011) GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol 12: R41.
26. Li C, Han J, Yao Q, Zou C, Xu Y, et al. (2013) Subpathway-GM: identification of metabolic subpathways via joint power of interesting genes and metabolites and their topologies within pathways. Nucleic Acids Res 41: e101.
27. Kohler S, Bauer S, Horn D, Robinson PN (2008) Walking the interactome for prioritization of candidate disease genes. Am J Hum Genet 82: 949-958.
28. Muller FL, Colla S, Aquilanti E, Manzo VE, Genovese G, et al. (2012) Passenger deletions generate therapeutic vulnerabilities in cancer. Nature 488: 337-342.
29. Hanash S (2004) Integrated global profiling of cancer. Nat Rev Cancer 4: 638-644.
30. Karinen S, Heikkinen T, Nevanlinna H, Hautaniemi S (2011) Data integration workflow for search of disease driving genes and genetic variants. PLoS One 6: e18636.
31. Shah N, Sukumar S (2010) The Hox genes and their roles in oncogenesis. Nat Rev Cancer 10: 361-371.
32. Senchenko VN, Krasnov GS, Dmitriev AA, Kudryavtseva AV, Anedchenko EA, et al. (2011) Differential expression of CHL1 gene during development of major human cancers. PLoS One 6: e15612.
33. Boulay PL, Cotton M, Melancon P, Claing A (2008) ADP-ribosylation factor 1 controls the activation of the phosphatidylinositol 3-kinase pathway to regulate epidermal growth factor-dependent growth and migration of breast cancer cells. J Biol Chem 283: 36425-36434.
34. Chang ZL (2010) Important aspects of Toll-like receptors, ligands and their signaling pathways. Inflamm Res 59: 791-808.
35. Zhu J, Mohan C (2010) Toll-like receptor signaling pathways-therapeutic opportunities. Mediators Inflamm 2010: 781235.
36. Basuyaux JP, Ferreira E, Stehelin D, Buttice G (1997) The Ets transcription factors interact with each other and with the c-Fos/c-Jun complex via distinct protein domains in a DNA-dependent and -independent manner. J Biol Chem 272: 26188-26195. (Pubitemid 27458828)
37. Tanjore H, Kalluri R (2006) The role of type IV collagen and basement membranes in cancer progression and metastasis. Am J Pathol 168: 715-717. (Pubitemid 43327723)
38. Nakano S, Iyama K, Ogawa M, Yoshioka H, Sado Y, et al. (1999) Differential tissular expression and localization of type IV collagen alpha1(IV), alpha2(IV), alpha5(IV), and alpha6(IV) chains and their mRNA in normal breast and in benign and malignant breast tumors. Lab Invest 79: 281-292. (Pubitemid 29166443)
39. Lee M, Daniels MJ, Venkitaraman AR (2004) Phosphorylation of BRCA2 by the Polo-like kinase Plk1 is regulated by DNA damage and mitotic progression. Oncogene 23: 865-872. (Pubitemid 38250931)
40. Carr HS, Zuo Y, Oh W, Frost JA (2013) Regulation of focal adhesion kinase activation, breast cancer cell motility, and amoeboid invasion by the RhoA guanine nucleotide exchange factor Net1. Mol Cell Biol 33: 2773-2786.
41. Saadatmand S, de Kruijf EM, Sajet A, Dekker-Ensink NG, van Nes JG, et al. (2013) Expression of cell adhesion molecules and prognosis in breast cancer. Br J Surg 100: 252-260.
42. Bazzoun D, Lelievre S, Talhouk R (2013) Polarity proteins as regulators of cell junction complexes: implications for breast cancer. Pharmacol Ther 138: 418-427.
43. Kim JH, Kim YW, Kim IW, Park DC, Lee KH, et al. (2013) Identification of candidate biomarkers using the Experion automated electrophoresis system in serum samples from ovarian cancer patients. Int J Oncol 42: 1257-1262.
44. Weigel MT, Banerjee S, Arnedos M, Salter J, A'Hern R, et al. (2013) Enhanced expression of the PDGFR/Abl signaling pathway in aromatase inhibitorresistant breast cancer. Ann Oncol 24: 126-133.
45. Anan K, Morisaki T, Katano M, Ikubo A, Kitsuki H, et al. (1996) Vascular endothelial growth factor and platelet-derived growth factor are potential angiogenic and metastatic factors in human breast cancer. Surgery 119: 333-339. (Pubitemid 26082669)
46. Shishido SN, Varahan S, Yuan K, Li X, Fleming SD (2012) Humoral innate immune response and disease. Clin Immunol 144: 142-158.
47. Pitteri SJ, Kelly-Spratt KS, Gurley KE, Kennedy J, Buson TB, et al. (2011) Tumor microenvironment-derived proteins dominate the plasma proteome response during breast cancer induction and progression. Cancer Res 71: 5090-5100.
48. Kranenburg O (2005) The KRAS oncogene: past, present, and future. Biochim Biophys Acta 1756: 81-82.
49. Downward J (2003) Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3: 11-22.
50. Key TJ, Appleby PN, Reeves GK, Roddam AW (2010) Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol 11: 530-542.
51. Sun Z, Asmann YW, Kalari KR, Bot B, Eckel-Passow JE, et al. (2011) Integrated analysis of gene expression, CpG island methylation, and gene copy number in breast cancer cells by deep sequencing. PLoS One 6: e17490.
52. Navlakha S, Kingsford C (2010) The power of protein interaction networks for associating genes with diseases. Bioinformatics 26: 1057-1063.
53. Wang X, Gulbahce N, Yu H (2011) Network-based methods for human disease gene prediction. Brief Funct Genomics 10: 280-293.